Health ❯ Healthcare ❯ Biotechnology

Therapeutics

Muscle Diseases RNAi-based Therapies Immunological Disorders ENCELTO Cancer Treatment Patient Outcomes Oligonucleotide Therapeutics Atopic Dermatitis Regulatory Affairs Monoclonal Antibodies

Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion

Genentech assumes late-stage development responsibilities following SanegeneBio's early work.

FDA Grants Orphan Drug Status to Cellenkos’ CK0804 for Myelofibrosis

FDA Approves First Eye Implant to Preserve Vision in Rare Macular Telangiectasia